Evidence memo

CJC-1295 / ipamorelin-style claims

Also tracked as: CJC-1295, Ipamorelin, GH secretagogue claims

Early endocrine signals exist, but internet claims often jump from hormone biomarkers to anti-aging, recovery, or body-composition outcomes.

Safety/regulatory watch Safety watch

Evidence status

Safety/regulatory watch. Evidence level: Safety/regulatory watch.

Whether GH/IGF-1 biomarker changes lead to net clinical benefit in the populations and claims being marketed.

The claims sound measurable because hormone biomarkers move, but biomarker movement is not the same as a clinical outcome.

There are early human endocrine and investigational signals. That does not establish long-term wellness benefit.

Long-term safety, cancer and cardiometabolic tradeoffs, product identity, and whether claimed outcomes are clinically demonstrated.

FDA compounding review and product-identity questions are central. This page does not provide obtaining or use guidance.

Regulatory updates, human outcome trials, safety data, and clearer distinction between endocrine signal and clinical benefit.

A biomarker-heavy claim cluster that needs far better outcome evidence.

PubMed

Teichman et al. · 2006

Early human endocrine signal; not a broad wellness outcome trial.

PubMed

Hellstrom et al. · 2014

Specific investigational context; not evidence for anti-aging or body-composition claims.

FDA

U.S. Food and Drug Administration · Current FDA page

Regulatory source for compounding-safety watch items; status should be rechecked before publication.